BKHABlack Hawk Acquisition Corporation
Is Black Hawk Acquisition struggling financially?
Yes, by its own account. Black Hawk Acquisition told the SEC on 15 Jul 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed Jul 2026
5/100
Critical
- Sector
- Biotech/Pharma
- Source filing
- 10-Q 15 Jul 2026
- Balance sheet
- 31 May 2026
Cash runway
-
0months
If the burn speeds up
Empty by May 2026
-
1month
If it eases off
Empty by Jul 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$0
÷
Cash burned over the last 12 months
$1.1M
What Black Hawk Acquisition told the SEC
…a Business Combination will be successful within the Combination Period. As a result, management has determined that such additional condition also raises substantial doubt about the Company’s ability to continue as a going concern. The unaudited financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Black Hawk Acquisition Corporation, Form 10-Q, filed 15 Jul 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
Other Biotech/Pharma companies that filed the doubt
- MAIA Maia Biotechnology $84.5M
- ESLA Estrella Immunopharma $32.0M
- ABVC ABVC BioPharma $23.7M
- ATPC Agape ATP $2.5M
- OSTX OS Therapies $73.3M
- PFSA Profusa $3.3M